LANSING, Mich., May 7, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 2024 RBC Capital Markets Global Healthcare Conference in New York, New York, on Tuesday, May 14, 2024.
John Adent, Neogen's Chief Executive Officer, will present at 4:05 PM Eastern Time.
To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Media Contact
Bill Waelke | VP, IR & Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.90 |
| Daily Change: | 0.01 0.17 |
| Daily Volume: | 2,702,602 |
| Market Cap: | US$1.280B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
